widenSN - New gold standard biomarker for Heart Failure (HF) patients

Heart failure (HF) affects about 64.3 million patients worldwide and is one of the costliest medical conditions due to long hospitalisations and frequent readmissions., HF patients have a high risk of sudden cardiac death (SCD) and 35% of them die in the first year. While there is no shortage of treatment options aimed at lowering the mortality risk of HF patients, the challenge is to accurately assess (and monitor) the patient’s risk for morbidity and mortality. A biomarker test to help identifying those HF patients could allow, for the first time, a personalization of the dose of drugs for each HF patient based on its risk profile, allowing a more informed balance between the drug’s side effects and patient’s risks. CardiNor has exclusive rights to the cardiac biomarker Secretoneurin (SN), an independent and strong predictor of mortality for HF, and other cardiovascular-related conditions like acute respiratory failure and severe sepsis. An SN test provide prognostic information that no other cardiac biomarker test offers, so there are valuable opportunities underlying the widespread use of SN in clinical practice worldwide. We will benefit from the IPN project to i) Generate substantial clinical evidence to support clinical guidance of how drugs prescribed for HF should be uptitrated per SN risk level to minimize risks, so all HF patients receive the best possible therapy over time; and ii) Obtain a stable, reproducible, and easily manufacturable assay that can be used as the core building block for a novel SN test in high-throughput Core Lab analysers of major IVD suppliers. widenSN is the opportunity for partners to jointly approach the global cardiac biomarkers market. SN holds potential to become a multi-million euro/year opportunity from 2024 onwards.

HF affects about 64.3 million patients worldwide and is one of the costliest medical conditions due to long hospitalisations and frequent readmissions. Since the heart is debilitated and uncapable of pumping properly, HF patients have a high risk of sudden cardiac death (SCD) and 35% of them die in the first year. While there is no shortage of treatment options aimed at lowering the mortality risk of HF patients, the challenge is to accurately assess (and monitor) the risk in acute and chronic stages. A biomarker for risk stratification of HF patients could allow, for the first time, a personalization of the dose of drugs for each HF patient based on its risk profile, allowing a more informed balance between the drug’s side effects and patient’s risks. CardiNor has exclusive rights to the cardiac biomarker Secretoneurin (SN), an independent and strong predictor of mortality for HF, cardiovascular-related acute respiratory failure and severe sepsis. SN holds prognostic information that no other cardiac biomarker offers, so there are valuable opportunities underlying the widespread use of SN in clinical practice worldwide. We will leverage from the IPN project to i) Generate substantial clinical evidence to support clinical guidance of how drugs prescribed for HF should be uptitrated per SN risk level to minimize risks, so all HF patients receive the best possible therapy over time; and ii) Obtain a stable, reproducible, and easily manufacturable assay that can be used as the core building block for a novel SN test in high-sensitivity immunochemical Core Lab analysers of major IVD brands. widenSN is the opportunity for partners to jointly approach the global cardiac biomarkers market and expand their EU’s competitive position. SN holds potential to become a multi-million euro/year opportunity from 2024 onwards, with >20% of revenues kept in Norway despite targeting a global value chain.